JCP

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
[Advanced]

Published Online First: 23 November 2007. doi:10.1136/jcp.2006.041830
Journal of Clinical Pathology 2008;61:689-696
Copyright © 2008 by the BMJ Publishing Group Ltd & Association of Clinical Pathologists.

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jcp.2006.041830v1
61/6/689    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Walker, R A
PubMed
Right arrow PubMed Citation
Right arrow Articles by Walker, R A
Topic Collections
Right arrow Editor's choice

DEMYSTIFIED

Immunohistochemical markers as predictive tools for breast cancer

R A Walker

Correspondence to:
Professor R A Walker, Department of Cancer Studies & Molecular Medicine, University of Leicester, Robert Kilpatrick Building, Leicester Royal Infirmary, PO Box 65, Leicester LE2 7LX, UK; raw14{at}le.ac.uk

Breast cancer is the predominant malignancy where oncologists use predictive markers clinically to select treatment options, with steroid receptors having been used for many years. Immunohistochemistry has taken over as the major assay method used for assessing markers. Despite its extensive use there are still issues around tissue fixation, methodology, interpretation and quantification. Although many markers have been evaluated, the oestrogen receptor remains the most reliable and best example of a predictor of treatment response. It is of major importance clinically that those undertaking interpretation of predictive markers understand the technical pitfalls and are aware of how expression of a particular marker relates to breast cancer pathology. A false negative or a false positive result will impact on patient management.








HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
Journal of Clinical Pathology Molecular Pathology
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 2008 by the BMJ Publishing Group Ltd & Association of Clinical Pathologists.